Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual Specificity CD19/CD22 CAR-T in R/R Lymphoma
NCT03468153Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous CD19/CD22 chimeric antigen receptor T-cells in lymphoma, sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
autologous CD19/CD22 chimeric antigen receptor T-cells
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT03468153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468153.